Europe

Alzheimer’s Research U.K. launches three Drug Discovery Institutes

Wednesday, February 18, 2015

Alzheimer’s Research U.K., a dedicated dementia research charity, has announced a $46.3 million Drug Discovery Alliance, launching three flagship Drug Discovery Institutes at the Universities of CambridgeOxford and University College London (UCL). The Drug Discovery Institutes will see 90 new research scientists employed in state-of-the-art facilities to fast-track the development of new treatments for Alzheimer’s disease and other dementias.

[Read More]

Genticel to continue per protocol its phase II study with ProCervix after review by DSMB

Thursday, January 29, 2015

Genticel, a French biotechnology company and developer of therapeutic vaccines, has announced that the Data and Safety Monitoring Board (DSMB), an independent committee of experts which monitors safety data every six months during a study, met as scheduled on Jan. 22. It recommended the RHEIA-VAC study proceed without any modifications. The DSMB already had made the same recommendation during the first review on July 1, 2014.

[Read More]

genae buys e-novex

Wednesday, January 28, 2015

genae, a global CRO and services provider, has acquired e-novex, a provider of electronic data tools for medical research. Both companies are based in Antwerp, Belgium.

[Read More]

EMA recommends suspending medicines over flawed studies

Monday, January 26, 2015

A number of medicines for which authorization in the European Union (E.U.) was primarily based on clinical studies conducted at GVK Biosciences in Hyderabad, India should be suspended, according to the EMA. The recommendation is based on findings from an inspection that raised concerns about how GVK conducted studies at the Hyderabad site on behalf of marketing authorization holders.

[Read More]

Syncona, UCLB form Autolus cancer immunotherapy company

Friday, January 23, 2015

Syncona, a London-based subsidiary of the Wellcome Trust, and UCL Business, the wholly-owned technology transfer company of University College London (UCL), have announced the creation of Autolus, a London-based biopharmaceutical company focused on the development and commercialization of next-generation engineered T-cell therapies for hematological and solid tumors. Autolus is founded upon the work of Dr. Martin Pule, an academic clinical hematologist and thought-leader in T-cell engineering. Syncona has committed $33.5 million to Autolus in a Series A financing. Dr. Christian Itin, former CEO of Micromet, has joined the company as chairman.

[Read More]